Related Experiment Video
Updated: Sep 2, 2025
08:52
Software-Assisted Quantitative Measurement of Osteoarthritic Subchondral Bone Thickness
Published on: March 18, 2022
3.1K
DL-3-N-Butylphthalide Promotes Cartilage Extracellular Matrix Synthesis and Inhibits Osteoarthritis Development by
Yaxin Zhang1, Jihang Dai2, Lianqi Yan2
1Dalian Medical University, Dalian 116044, China.
Oxidative Medicine and Cellular Longevity
|August 1, 2022
Summary
DL-3-n-butylphthalide (NBP) inhibits osteoarthritis progression by promoting cartilage repair and reducing cell death. This celery seed extract activates FoxO3a, offering a potential new treatment for this degenerative joint disease.
Area of Science:
- Biochemistry
- Cell Biology
- Pharmacology
Background:
- Osteoarthritis (OA) is a degenerative joint disease with no effective treatments.
- DL-3-n-butylphthalide (NBP), from celery seeds, has shown antioxidant and anti-inflammatory properties.
- The therapeutic potential of NBP for OA remains largely unexplored.
Purpose of the Study:
- To investigate the effects of NBP on osteoarthritis (OA) in vitro and in vivo.
- To elucidate the underlying molecular mechanisms of NBP's action in OA.
Main Methods:
- An in vivo rat model of osteoarthritis (DMM+ACLT) was used to assess NBP's therapeutic effect.
- In vitro studies utilized human osteoarthritic chondrocytes and cartilage explants.
- Key molecular pathways, including PI3K/AKT and FoxO3a, were analyzed.
Main Results:
- NBP injection inhibited osteoarthritis development in the rat model.
- NBP increased the expression of cartilage matrix components (collagen II, aggrecan) and antioxidant enzymes (SOD, CAT).
- NBP upregulated FoxO3a by inhibiting the PI3K/AKT pathway, reducing chondrocyte apoptosis.
Conclusions:
- NBP demonstrates potential for treating osteoarthritis by enhancing cartilage matrix synthesis.
- NBP inhibits OA progression and chondrocyte apoptosis through FoxO3a activation.
- NBP represents a promising therapeutic agent for osteoarthritis management.
